Insight Genetics will use a $1.5 million grant from the National Cancer Institute to further develop its non-small cell lung cancer diagnostic test. Specifically, Insight said it will develop a panel of tests for detecting and characterizing oncogenic DEPDC1, RET and ROS1 in NSCLC patients who have tested triple negative for KRAS, EGFR or ALK gene mutations.

Related Summaries